Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise against tough head and neck cancers

NCT ID NCT07065630

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called volrustomig combined with standard chemotherapy (paclitaxel and carboplatin) in people with advanced head and neck cancer that is not caused by HPV. The goal is to see if this combination shrinks tumors before further treatment is tailored based on how well the cancer responds. About 38 adults with untreated, locally advanced HPV-negative head and neck cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER HPV

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••